BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26910788)

  • 1. Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
    Charles PD; Manack Adams A; Davis T; Bradley K; Schwartz M; Brin MF; Patel AT
    Pain Pract; 2016 Nov; 16(8):1073-1082. PubMed ID: 26910788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).
    Jankovic J; Adler CH; Charles D; Comella C; Stacy M; Schwartz M; Manack Adams A; Brin MF
    J Neurol Sci; 2015 Feb; 349(1-2):84-93. PubMed ID: 25595221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
    Charles PD; Adler CH; Stacy M; Comella C; Jankovic J; Manack Adams A; Schwartz M; Brin MF
    J Neurol; 2014 Jul; 261(7):1309-19. PubMed ID: 24752807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE.
    Agarwal P; Barbano R; Moore H; Schwartz M; Zuzek A; Sadeghi M; Patel A
    Front Neurol; 2022; 13():914486. PubMed ID: 35847221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe.
    Petitclerc M; Cloutier M; Naud P; Langlois M; Bhogal M; Davidovic G
    Can J Neurol Sci; 2021 Sep; 48(5):676-684. PubMed ID: 33342445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).
    Jankovic J; Adler CH; Charles PD; Comella C; Stacy M; Schwartz M; Sutch SM; Brin MF; Papapetropoulos S
    BMC Neurol; 2011 Nov; 11():140. PubMed ID: 22054223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study.
    Kongsaengdao S; Arayawithchanont A; Samintharapanya K; Rojanapitayakorn P; Maneeton B; Maneeton N
    Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34678987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.
    Patel AT; Lew MF; Dashtipour K; Isaacson S; Hauser RA; Ondo W; Maisonobe P; Wietek S; Rubin B; Brashear A
    PLoS One; 2021; 16(2):e0245827. PubMed ID: 33524060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.
    Trosch RM; Espay AJ; Truong D; Gil R; Singer C; LeWitt PA; Lew MF; Tagliati M; Adler CH; Chen JJ; Marchese D; Comella CL
    J Neurol Sci; 2017 May; 376():84-90. PubMed ID: 28431634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study.
    Dashtipour K; Mari Z; Jankovic J; Adler CH; Schwartz M; Brin MF
    J Neurol Sci; 2019 Oct; 405():116413. PubMed ID: 31494402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
    Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
    Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multichannel Electromyographic Mapping to Optimize OnabotulinumtoxinA Efficacy in Cervical Dystonia.
    Kilbane C; Ostrem J; Galifianakis N; Grace J; Markun L; Glass GA
    Tremor Other Hyperkinet Mov (N Y); 2012; 2():. PubMed ID: 23439966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry.
    Molho ES; Stacy M; Gillard P; Charles D; Adler CH; Jankovic J; Schwartz M; Brin MF
    Mov Disord Clin Pract; 2016; 3(2):130-138. PubMed ID: 27774495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact.
    Jankovic J; Tsui J; Brin MF
    Medicine (Baltimore); 2023 Jul; 102(S1):e32403. PubMed ID: 37499081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan.
    Kaji R; Endo A; Sugawara M; Ishii M
    eNeurologicalSci; 2021 Dec; 25():100374. PubMed ID: 34877415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
    J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.
    Fernandez HH; Pappert EJ; Comella CL; Evidente VG; Truong DD; Verma A; Jankovic J
    Tremor Other Hyperkinet Mov (N Y); 2013; 3():. PubMed ID: 23610743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia.
    Chinnapongse R; Pappert EJ; Evatt M; Freeman A; Birmingham W
    Int J Neurosci; 2010 Nov; 120(11):703-10. PubMed ID: 20942584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.